非小细胞肺癌表皮生长因子受体酪氨酸激酶抑制剂(英文).pptVIP

YMC Epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer Yuh-Min Chen, MD, PhD. Chest Dept., Taipei VGH Activation of the epidermal growth factor receptor tyrosine kinase (EGFR-TK): a pivotal driver of carcinogenesis IDEAL 1 and 2 trial design IDEAL 1 and 2: overall survival by symptom improvement (250 mg/day) ISEL (IRESSA Survival Evaluation in Lung Cancer): Clinical Trial Design ISEL - Overall Survival ISEL Survival: Orientals RESULTS 3 CR, 9 PR, with a R.R. of 33.3% SD 14, control rate of 72.2% All treatment-related toxicities were few and mild in severity, except one patient suffered from reversible grade 3 interstitial pneumonitis Study Design of BR.21 BR.21: Significant clinical predictors of response to Tarceva Improvement in Survival with Tarceva BR.21: Time to symptom deterioration (months) TRUST: Tarceva MO18109An expanded access clinical program of Tarceva (erlotinib) in pts with advanced stage IIIB/IV NSCLCLung Cancer 2008 Patient Population Response From May 2005 to July 2006, 300 patients were entered from 14 hospitals in Taiwan. This analysis was based on 299 patients who received at least one dose of Tarceva. Response rate and control rate by pretreatment characteristics and skin toxicity EGFR-TKI vs. chemotherapeutic agents in salvage chemotherapy Efficacy of Salvage Therapy in NSCLC INTEREST (gefitinib vs. docetaxel in pts with LA or meta. NSCLC pre-treated with platinum-based chemotherapy QoF and symptom improvement Overall survival Clinical characteristics response rate (pt number=1974) EGFR Mutation Failure of Doublet Chemotherapy plus EGFR-TKI INTACT I, II TRIBUTE, TALENT Can we further prolong disease-free survival and overall survival ? Failure of doublet chemotherapy plus TKI INTACT I, II (Gefitinib); TRIBUTE, TALENT (Erlotinib) Majority performed in Caucasian pts Unknown for Asian pts with high EGFR mutation rate To assess the efficacy of adding chronic intermittent low-dose vinorelbine to gefiti